NCT01638533
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: Neuroendocrine tumor (NET)
Recruitment Status: Active, not recruiting
Phase 1
Drug Category: Misc Inhibitor

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: Liver
Additional Notes: Diagnosis of NET not required, but NET patients are eligible
Exclusions: Symptomatic or untreated brain metastases- see trial for details
https://ClinicalTrials.gov/show/NCT01638533